Brief: Attana Says Has Obtained CE-IVD Marking For Its First Products Within Clinical Diagnostics
29/06/2021 18:10
June 29 (Reuters) - Attana AB ATANA.NGM :
* ATTANA AB - REGISTERED AVA SARS-COV-2 IGG IMMUNOASSAY &
ANALYTICAL INSTRUMENT ATTANA CELL 250 FOR CE-IVD MARKING WITH
SWEDISH MEDICAL PRODUCTS AGENCY
* ATTANA - AMBITION IS TO SEEK REGULATORY APPROVAL FOR
QUALITY
ASSESSMENT OF SARS-COV-2 IGG ANTIBODIES BASED ON ATTANA'S
INSTRUMENTS AND TEST KITS
Source text for Eikon: urn:newsml:reuters.com:*:nPrepHz7ha
Further company coverage: ATANA.NGM
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ATTANA AB
See all newsBrief: Attana Says Co Has Begun Discussion About Moving Production Of Consumables To Arocell AB
Brief: Attana Q3 Pretax Loss Widens To SEK 3.0 Mln
Brief: Attana Signs Distribution Agreement Fow Sweden With Triolab
Brief: Attana Says Has Obtained CE-IVD Marking For Its First Products Within Clinical Diagnostics
Brief: Attana AB Attana And Triolab Sign MoU On Distribution Of Attana's Diagnostic Offer